1. What is the EndoPredict test?
EndoPredict is a test that predicts how likely breast cancer is to spread to somewhere else in the body. It’s suitable for some people who will be taking hormone therapy for at least 5 years.
EndoPredict can help your treatment team decide whether you would benefit from having .
2. Who EndoPredict is for
EndoPredict may be suitable if you’ve recently been diagnosed with:
- Early stage breast cancer
- That is oestrogen receptor positive (ER-positive)
- And HER2-negative
If cancer is in 1 to 3 lymph nodes
If breast cancer has spread to 1 to 3 lymph nodes under the arm, EndoPredict may be offered to:
- Women who have been through the menopause
- Men
- Some trans, non-binary or intersex people
If there’s no cancer in the lymph nodes
EndoPredict may be offered to help you decide whether to have chemotherapy if:
- Breast cancer has not spread to any lymph nodes, or if a small amount of cancer is in the lymph nodes (micrometastases)
- And you’ve been told you have an intermediate risk of breast cancer spreading to another part of the body
3. Why it's used
Benefits of chemotherapy for primary breast cancer
Whether you are offered chemotherapy depends on several factors. Read more about the benefits of chemotherapy and whether chemotherapy is th...
Your specialist may recommend the EndoPredict test to help decide if other treatments, particularly chemotherapy, are needed.
Chemotherapy may be given after surgery to reduce the risk of breast cancer coming back in future.
Whether you’re offered chemotherapy depends on a number of features of your breast cancer. These include:
- The size and grade of the cancer
- Whether it has spread to any of the lymph nodes under the arm
- Whether the cancer is hormone receptor and HER2 positive or negative
For some people the benefit of chemotherapy is clear, but for others it’s less clear.
4. How it works
How the test is done
The test is done on a small amount of breast cancer tissue already removed (for example during a or surgery). The tissue is sent to a laboratory, usually outside your local hospital and sometimes in Germany, where the test is carried out.
The test looks at groups of genes found in breast cancer and features of the breast cancer to produce a score.
If your specialist has recommended you have hormone therapy before surgery, the test must be done on the tissue removed by a core biopsy before you start hormone therapy.
How long results take
The results are given separately from your pathology report and are sent to your specialist usually within 7 to 10 days.
5. EndoPredict score
The test gives a score, known as an EPclin Risk score, that's reported as either low or high risk.
Your specialist will use this score, along with other information about your breast cancer, to help decide what treatment to recommend.
Low risk: EPclin Risk score 0 to 3.3
A low risk score means it’s unlikely the breast cancer will spread to somewhere else in the body.
Most people with a low risk score will not need chemotherapy.
High risk: EPclin Risk score over 3.3
A high risk score means it’s more likely the breast cancer will spread to somewhere else in the body.
Chemotherapy is recommended for most people with a high risk score.
6. Availability and cost
Your pathology results
Your pathology results give details about your breast cancer that can help decide the treatment you’re offered. Read our guide to pathology ...
If EndoPredict is suitable for you, it’s usually available on the NHS across the UK.
Most private healthcare companies will also cover the cost of the test.
You can also pay for the test yourself. Your treatment team will need to order the test for you and will be sent the results to discuss with you. It costs around £1,500.
